Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIOP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) SEC filings page provides access to regulatory documents filed by Fortress Biotech, Inc. with the U.S. Securities and Exchange Commission. According to Form 8-K filings, FBIOP is the trading symbol for the company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, which is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Capital Market alongside the common stock (FBIO).
In the available Form 8-K filings, Fortress Biotech reports material events such as quarterly financial results, annual meeting voting outcomes and other corporate updates. These filings identify both the common stock and the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock in the table of securities registered pursuant to Section 12(b), confirming their listing on the Nasdaq Capital Market. The filings also indicate that Fortress Biotech is incorporated in Delaware.
Within the company’s financial statements, which are referenced in press releases and may be included in periodic reports, the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock appears as cumulative redeemable perpetual preferred stock with a designated number of Series A shares issued and outstanding and a stated liquidation value per share. These disclosures help investors understand how the preferred stock fits into Fortress Biotech’s capital structure alongside common equity, additional paid-in capital, accumulated deficit and non-controlling interests.
On this page, users can review SEC filings such as Form 8-K that mention FBIOP and Fortress Biotech’s preferred stock, as well as filings that discuss results of operations, financial condition and stockholder votes. AI-powered tools can assist in summarizing lengthy filings and highlighting sections that reference the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, the company’s registered securities table and key financial statement line items. This allows readers to quickly identify how Fortress Biotech describes FBIOP within its official regulatory disclosures and how the preferred stock relates to the company’s overall financial reporting.
Fortress Biotech’s chairman, president and CEO Lindsay A. Rosenwald filed Amendment No. 5 to his Schedule 13D, reporting beneficial ownership of 6,917,715 shares of common stock, or 20.7% of the company, based on 31,037,937 shares outstanding as reported in a December 2025 prospectus supplement.
The position includes 4,050,765 issued shares held directly, 475,424 unvested restricted shares subject to repurchase, 2,330,874 shares underlying currently exercisable warrants, and smaller holdings through Paramount Biosciences, LLC and Capretti Grandi LLC over which he has voting and dispositive control. It excludes 96,919 shares held by family trusts where he lacks such control.
The amendment reflects equity grants of 454,153 shares on January 1, 2025 and 475,424 shares on March 18, 2026 under Fortress Biotech’s Long Term Incentive Plan, awarded after he achieved 100% of goals set by the compensation committee. Rosenwald states he has no present plans for major corporate actions or additional acquisitions or dispositions beyond this compensation-related ownership.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.
Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.
WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.
Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.
Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.
Fortress Biotech, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended June 30, 2025.
The press release is included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.